33 results
Thumbnail

D1.466 - Atopic dermatitis increases the risk of chronic systemic diseases in children and adolescents: a nationwide nested case–control study

Thumbnail

D1.472 - Features of the intestinal microbiota composition in infants with allergy: comparison of two diagnostic methods

Thumbnail

D1.473 - Features of the intestinal microbiota composition in infants with IgE- and non-IgE-mediated allergy

Thumbnail

D1.476 - Impact of neonatal vaccination on the incidence of atopic dermatitis in children by 36 months: a prospective cohort study

Thumbnail

D1.480 - Polysomnographic phenotypes of sleep-disordered breathing in children with asthma: a systematic review

Thumbnail

D1.467 - Economic Burden of Allergic Diseases in Children: Global Evidence and Implications for Kyrgyzstan

Thumbnail

D1.468 - Association Between Autism Spectrum Disorder and Skin Barrier Integrity

Thumbnail

D1.470 - Comparison of long-term (52 week therapy) maintenance vs. as-needed intranasal corticosteroid therapy in pediatric allergic rhinitis: assessment using exhaled breath condensate leukotriene E4

Thumbnail

D1.471 - From Grandmother to Granddaughter: A Case Report of Hereditary Angioedema Diagnosed in the Third Generation

Thumbnail

D1.475 - Significance of air-trapping and pulmonary hyperinflation in the severity of broncho-obstructive manifestations in children with cystic fibrosis

Thumbnail

D1.478 - Hyper-IgE in allergic bronchopulmonary aspergillosis: diagnostic challenges

Thumbnail

D1.479 - Lung function in children with cystic fibrosis associated with wheezing

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial

Thumbnail

D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to